I thoroughly enjoyed hearing Dr. Brian Durie’s abstract presentation on “Myeloma: Therapy, excluding Transplantation: Advances in Newly Diagnosed and Relapsed Myeloma.” He presented that the combination of VELCADE® (bortezomib), Revilmid® (lenalidomide), and dexamethasone (also called VRd), with continuous maintenance of lenalidomide and dexamethasone significantly improves progression-free survival and overall survival. This VRd regimen along with lenalidomide and dexamethasone maintenance could be the new standard treatment for patients with myeloma.
I feel optimistic every time I listen to Dr. Durie. Seeing his passion gives me great relief and comfort knowing I have someone like him fighting for me.
Follow Carlene on Twitter: @IMFprattMYELOMA
The Upland CA Multiple Myeloma Support Group